Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a global pandemic. The development of an acquired thrombophilia with activation of the coagulation cascade in response to the inflammatory process has been described.[@bib1] SARS-CoV-2 appears to have an affinity for angiotensin-converting enzyme 2 receptors that seem to be downregulated, which may drive the proinflammatory/prothrombotic consequences.[@bib2]

As this is a novel illness, there has been limited opportunity to understand and to investigate the effect of SARS-CoV-2. In severe disease, there appears to be elevation of D-dimer levels. Prolongation of prothrombin time and activated partial thromboplastin time seems to be associated with an increased risk of acute respiratory distress syndrome and death.[@bib3] The development of disseminated intravascular coagulation appears to be common in nonsurvivors.[@bib4]

There appears to be an increased risk of pulmonary thromboembolic events in ventilated patients with SARS-CoV-2, despite the administration of low-molecular-weight heparin prophylaxis. In a small series of minimally invasive autopsies, a significant proportion of patients were found to have small fibrinous thrombi in pulmonary arterioles.[@bib1] Similar data have been described across Europe with revision of low-molecular-weight heparin prophylaxis dosing. As well as the described pulmonary thrombotic complications, a series of early circuit occlusions has been encountered in patients on hemofiltration as a consequence of multiple organ dysfunction syndrome from SARS-CoV-2.

Recently, a small number of patients have presented with systemic intra-arterial thrombosis and a diagnosis of SARS-CoV-2. There is some evidence to suggest that this may occur, with a small series reporting ischemic strokes in patients in intensive care units.[@bib5] In our experience, patients presenting with limb-threatening ischemia and SARS-CoV-2 have had no other clear reason for development of intra-arterial thrombosis. Management has been dictated primarily by the severity of the organ dysfunction. A conservative approach with the prescription of therapeutic low-molecular-weight-heparin with subsequent conversion to a direct-acting oral anticoagulant has been an effective strategy.

Vascular surgeons have to recognize the potential for limb- and life-threatening arterial occlusion events in patients with SARS-CoV-2. Further research is required to try to elucidate the mechanisms by which this disease process activates the coagulation cascade.
